Content area
Full Text
Presentation
JAMES FITTER, CHIEF EXECUTIVE OFFICER, EXECUTIVE DIRECTOR, ONEVIEW HEALTHCARE PLC: Thanks very much and good morning, everyone in Australia, good afternoon to those here in the United States where I'm calling from and in Dublin, Ireland, good evening to my colleagues who will be joining me very shortly.
So firstly, just the usual legal disclaimer around, particularly around forward-looking statements, which I encourage you to read. I'd also just remind you that all amounts in the presentation are in euros, which remains our reporting currency unless otherwise specified. And of course, we are referring to full year results for the year ended December 2023.
Joining me on the call today is Helena, our Chief Financial Officer; Niall, our Chief Product and Strategy Officer; and JP, our Chief Operating Officer, who are going to be updating you on a couple of the key developments in their respective sections. Just a reminder, our vision is to power personalized exemplary care experiences.
In the agenda today, we are going to obviously look at the 2023 year-end review. Niall is going to speak to one of the key growth drivers, which is our Virtual Care strategy. He's also going to talk about MyStay Mobile, which is the product formerly known as BYOD, which we very successfully launched here in Los Angeles.
I'm currently at the ViVE Health Care Conference, very large gathering here in Los Angeles. We're having a fantastic response to launch of that product. And then JP is managing the Baxter partnership for us, and he's going to provide some real updates on where we're at with the Baxter partnership. Of course, I will then conclude by sharing our outlook on 2024 and hopefully leave plenty of time for your questions.
So let's start with the 2023 review. I'm not going to steal too much of Helena's thunder. And these high-level numbers should come as no surprise because we telegraphed them in our 4C, which we released at the start of January.
So total revenue for the year is at EUR9.4 million, recurring revenue at EUR6.6 million. Very pleased with the improvement in gross margin, which has improved by 6%. And of course, I'm very pleased with the strong cash balance to finish the year. But...